• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

普通人群中 COVID-19 疫苗接种和/或感染后的 SARS-CoV-2 体液免疫反应异质性。

Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population.

机构信息

Institut Pierre-Louis d'Épidémiologie et de Santé Publique, Sorbonne Université, Inserm, Département de santé publique, Hôpital Saint-Antoine, APHP, 27 rue Chaligny, 75571, Paris Cedex 12, France.

Unité des Virus Émergents, UVE, IRD 190, INSERM 1207, Aix Marseille Univ, IHU Méditerranée Infection, Marseille, France.

出版信息

Sci Rep. 2022 May 21;12(1):8622. doi: 10.1038/s41598-022-11787-4.

DOI:10.1038/s41598-022-11787-4
PMID:35597776
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9123863/
Abstract

Assessment of the intensity, dynamics and determinants of the antibody response after SARS-CoV-2 infection or vaccination in the general population is critical to guide vaccination policies. This study characterized the anti-spike IgG titers in 13,971 participants included in a French multicohort population-based serological survey on COVID-19 between April and October 2020 and followed-up with serological testing between May and October 2021. Eight follow-up profiles were defined depending on SARS-CoV-2 infection (0, 1 or 2) and COVID-19 vaccination (0, 1, 2 or 3). The anti-spike titer was lower in adults with no vaccination even in case of infection or reinfection, while it was higher in adults with infection followed by vaccination. The anti-spike titer was negatively correlated with age in vaccinated but uninfected adults, whereas it was positively correlated with age in unvaccinated but infected adults. In adults with 2 vaccine injections and no infection, the vaccine protocol, age, gender, and time since the last vaccine injection were independently associated with the anti-spike titer. The decrease in anti-spike titer was much more rapid in vaccinated than in infected subjects. These results highlight the strong heterogeneity of the antibody response against SARS-CoV-2 in the general population depending on previous infection and vaccination.

摘要

评估普通人群感染 SARS-CoV-2 或接种疫苗后的抗体反应强度、动态和决定因素对于指导疫苗接种政策至关重要。本研究对 2020 年 4 月至 10 月期间参加法国多队列基于人群的 COVID-19 血清学调查的 13971 名参与者的抗刺突 IgG 滴度进行了特征描述,并在 2021 年 5 月至 10 月期间进行了血清学检测。根据 SARS-CoV-2 感染(0、1 或 2)和 COVID-19 疫苗接种(0、1、2 或 3)定义了 8 种随访特征。即使感染或再次感染,未接种疫苗的成年人的抗刺突滴度也较低,而感染后接种疫苗的成年人的抗刺突滴度较高。在接种疫苗但未感染的成年人中,抗刺突滴度与年龄呈负相关,而在未接种疫苗但感染的成年人中,抗刺突滴度与年龄呈正相关。在接种 2 剂疫苗且未感染的成年人中,疫苗接种方案、年龄、性别和最后一次疫苗接种后时间与抗刺突滴度独立相关。在接种疫苗的人群中,抗刺突滴度的下降速度明显快于感染人群。这些结果强调了普通人群对 SARS-CoV-2 的抗体反应存在很强的异质性,取决于先前的感染和接种情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5ae/9124198/6c10432d79c7/41598_2022_11787_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5ae/9124198/ea1003f64255/41598_2022_11787_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5ae/9124198/97c2aad54231/41598_2022_11787_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5ae/9124198/2b86a6cdd61f/41598_2022_11787_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5ae/9124198/6c10432d79c7/41598_2022_11787_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5ae/9124198/ea1003f64255/41598_2022_11787_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5ae/9124198/97c2aad54231/41598_2022_11787_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5ae/9124198/2b86a6cdd61f/41598_2022_11787_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d5ae/9124198/6c10432d79c7/41598_2022_11787_Fig4_HTML.jpg

相似文献

1
Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population.普通人群中 COVID-19 疫苗接种和/或感染后的 SARS-CoV-2 体液免疫反应异质性。
Sci Rep. 2022 May 21;12(1):8622. doi: 10.1038/s41598-022-11787-4.
2
Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?mRNA SARS-CoV-2 疫苗接种后抗刺突抗体的持久性在既往感染者中更长:是否可以延迟加强针接种?
Infection. 2022 Dec;50(6):1573-1577. doi: 10.1007/s15010-022-01816-9. Epub 2022 Apr 7.
3
Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.维持性透析患者接种 SARS-CoV-2 疫苗后 6 个月的血清学反应。
Clin J Am Soc Nephrol. 2022 Mar;17(3):403-413. doi: 10.2215/CJN.12250921. Epub 2022 Feb 10.
4
Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity.严重肥胖人群对 SARS-CoV-2 疫苗的抗体反应。
Obes Surg. 2022 Sep;32(9):2987-2993. doi: 10.1007/s11695-022-06181-y. Epub 2022 Jul 8.
5
A longitudinal seroepidemiology study to evaluate antibody response to SARS-CoV-2 virus infection and vaccination in children in Calgary, Canada from July 2020 to April 2022: Alberta COVID-19 Childhood Cohort (AB3C) Study.一项在加拿大卡尔加里开展的纵向血清流行病学研究,旨在评估 2020 年 7 月至 2022 年 4 月期间儿童对 SARS-CoV-2 病毒感染和疫苗接种的抗体反应:艾伯塔省 COVID-19 儿童队列(AB3C)研究。
PLoS One. 2023 Apr 6;18(4):e0284046. doi: 10.1371/journal.pone.0284046. eCollection 2023.
6
Immune response to COVID-19 vaccination in a population with and without a previous SARS-CoV-2 infection.有和没有既往 SARS-CoV-2 感染人群对 COVID-19 疫苗接种的免疫反应。
Ir J Med Sci. 2023 Apr;192(2):731-739. doi: 10.1007/s11845-022-03044-4. Epub 2022 Jun 9.
7
Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals.接种疫苗人群中 SARS-CoV-2 病毒中和抗体滴度与刺突抗体和 ACE2 抑制的相关性。
Microbiol Spectr. 2022 Oct 26;10(5):e0131522. doi: 10.1128/spectrum.01315-22. Epub 2022 Sep 19.
8
Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.理解“混合免疫”:对严重急性呼吸综合征冠状病毒 2 感染(SARS-CoV-2)和 2019 年冠状病毒病(COVID-19)疫苗的体液免疫反应的比较和预测因素。
Clin Infect Dis. 2023 Feb 8;76(3):e439-e449. doi: 10.1093/cid/ciac392.
9
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.真实世界中衰弱老年人接受延长间隔和异源 COVID-19 mRNA 疫苗接种后的血清学反应(UNCoVER):一项前瞻性观察队列研究的中期报告。
Lancet Healthy Longev. 2022 Mar;3(3):e166-e175. doi: 10.1016/S2666-7568(22)00012-5. Epub 2022 Feb 23.
10
Evaluation of the Roche SARS-CoV-2 Rapid Antibody Test in Samples from Vaccinated Individuals.罗氏新型冠状病毒快速抗体检测在接种个体样本中的评估。
Microbiol Spectr. 2022 Jun 29;10(3):e0270921. doi: 10.1128/spectrum.02709-21. Epub 2022 May 16.

引用本文的文献

1
Reinfection with a Bacterial Pathogen Augments Heterogeneity in Host Disease Responses.细菌病原体的再次感染会增加宿主疾病反应的异质性。
Res Sq. 2025 Jul 3:rs.3.rs-6856045. doi: 10.21203/rs.3.rs-6856045/v1.
2
Placental transfer of SARS-CoV-2 antibodies in mother-neonate pairs: a prospective nested cohort study.母婴对中 SARS-CoV-2 抗体的胎盘转运:一项前瞻性巢式队列研究。
BMC Infect Dis. 2025 Jul 1;25(1):875. doi: 10.1186/s12879-025-11225-6.
3
Multiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?

本文引用的文献

1
Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection.BNT162b2 mRNA疫苗接种或SARS-CoV-2感染后抗体滴度衰减的大规模研究
Vaccines (Basel). 2021 Dec 31;10(1):64. doi: 10.3390/vaccines10010064.
2
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans.BNT162b2 与 mRNA-1273 疫苗在美国退伍军人中的比较效力。
N Engl J Med. 2022 Jan 13;386(2):105-115. doi: 10.1056/NEJMoa2115463. Epub 2021 Dec 1.
3
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
新冠病毒疫苗接种前后的多发性硬化症发病:HLA单倍型能否成为决定因素?
Int J Mol Sci. 2024 Apr 22;25(8):4556. doi: 10.3390/ijms25084556.
4
Relatively preserved functional immune capacity with standard COVID-19 vaccine regimen in people living with HIV.与标准 COVID-19 疫苗方案相比,HIV 感染者具有相对保留的功能性免疫能力。
Front Immunol. 2023 Sep 4;14:1204314. doi: 10.3389/fimmu.2023.1204314. eCollection 2023.
5
SARS-CoV-2 vaccination and infection in ozanimod-treated participants with relapsing multiple sclerosis.奥扎莫德治疗的复发型多发性硬化症患者的 SARS-CoV-2 疫苗接种和感染情况。
Ann Clin Transl Neurol. 2023 Oct;10(10):1725-1737. doi: 10.1002/acn3.51862. Epub 2023 Aug 7.
6
Heterogeneity in Vaccinal Immunity to SARS-CoV-2 Can Be Addressed by a Personalized Booster Strategy.针对新冠病毒的疫苗免疫异质性可通过个性化加强策略来解决。
Vaccines (Basel). 2023 Apr 6;11(4):806. doi: 10.3390/vaccines11040806.
7
Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients.BNT162b2疫苗接种者中奥密克戎亚谱系BA.5和重组XBB对抗体中和的逃逸情况
Microorganisms. 2023 Jan 12;11(1):191. doi: 10.3390/microorganisms11010191.
8
Serological Responses up to 9 Months following COVID-19 mRNA Vaccination in Residents and Health-Care Workers of Long-Term Care Facilities: A Multicenter Prospective Cohort Study in Northern Italy.长期护理机构居民和医护人员接种新冠病毒mRNA疫苗后9个月内的血清学反应:意大利北部的一项多中心前瞻性队列研究
Vaccines (Basel). 2022 Dec 19;10(12):2183. doi: 10.3390/vaccines10122183.
9
Usefulness and Limitations of Anti-S IgG Assay in Detecting Previous SARS-CoV-2 Breakthrough Infection in Fully Vaccinated Healthcare Workers.抗S IgG检测在检测完全接种疫苗的医护人员既往新冠病毒突破性感染中的应用价值及局限性
Diagnostics (Basel). 2022 Sep 4;12(9):2152. doi: 10.3390/diagnostics12092152.
在英国,用 ChAdOx1 nCov-19 或 BNT162b2 接种两剂后作为第三剂(加强针)接种 7 种 COVID-19 疫苗的安全性和免疫原性(COV-BOOST):一项盲法、多中心、随机、对照、2 期试验。
Lancet. 2021 Dec 18;398(10318):2258-2276. doi: 10.1016/S0140-6736(21)02717-3. Epub 2021 Dec 2.
4
Immunogenicity trends 1 and 3 months after second BNT162B2 vaccination among healthcare workers in Israel.以色列医护人员第二次接种 BNT162B2 疫苗后 1 和 3 个月的免疫原性趋势。
Clin Microbiol Infect. 2022 Mar;28(3):450.e1-450.e4. doi: 10.1016/j.cmi.2021.11.014. Epub 2021 Nov 24.
5
Age, COVID-19-like symptoms and SARS-CoV-2 seropositivity profiles after the first wave of the pandemic in France.法国大流行第一波后年龄、类似 COVID-19 的症状和 SARS-CoV-2 血清阳性特征。
Infection. 2022 Feb;50(1):257-262. doi: 10.1007/s15010-021-01731-5. Epub 2021 Nov 25.
6
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis.中和抗体滴度作为预测对 SARS-CoV-2 变异体的保护作用以及加强免疫的影响的指标:一项荟萃分析。
Lancet Microbe. 2022 Jan;3(1):e52-e61. doi: 10.1016/S2666-5247(21)00267-6. Epub 2021 Nov 15.
7
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.BNT162b2和mRNA-1273新冠疫苗在卡塔尔针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)德尔塔变种的有效性
Nat Med. 2021 Dec;27(12):2136-2143. doi: 10.1038/s41591-021-01583-4. Epub 2021 Nov 2.
8
Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar.卡塔尔既往感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)与mRNA疫苗接种后突破性感染风险的关联
JAMA. 2021 Nov 16;326(19):1930-1939. doi: 10.1001/jama.2021.19623.
9
Waning Immunity after the BNT162b2 Vaccine in Israel.以色列接种 BNT162b2 疫苗后的免疫力下降。
N Engl J Med. 2021 Dec 9;385(24):e85. doi: 10.1056/NEJMoa2114228. Epub 2021 Oct 27.
10
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.mRNA 疫苗可诱导对 SARS-CoV-2 及其关注变种的持久免疫记忆。
Science. 2021 Dec 3;374(6572):abm0829. doi: 10.1126/science.abm0829.